Jade Biosciences Inc. Financials

JBIO

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 6 available years

Income Statement	DEC 2025 ~38.4:1 split	DEC 2024	DEC 2023	DEC 2022 2:1 split	DEC 2021 ~50.8:1 split
General & Administrative	$20	$21	$17	$15	$8
Research & Development	$93	$53	$64	$39	$15
Total Operating Expenses	$114	$75	$81	$53	$23
Operating Income	-$114	-$75	-$81	-$53	-$23
Other Non-Operating Income (Expense)	-$14	$5	$6	$2	$0
EBT (Earnings Before Tax)	-$127	-$70	-$75	-$51	-$23
Income Tax Expense	$0	$0	$0	$0	$0
Net Income
Net Income	-$127	-$70	-$76	-$52	-$23
EPS (Basic)	-$3.19	-$85.40	-$100.45	-$73.50	-$65.45
EPS (Diluted)	-$3.19	-$85.40	-$100.45	-$73.50	-$65.45
Weighted Avg Shares (Basic)	31.4M	28.6M	26.3M	24.5M	12.3M
Weighted Avg Shares (Diluted)	31.4M	28.6M	26.3M	24.5M	12.3M
Shares Outstanding	31.4M	816,634.114	752,332.286	699,202.971	351,246.543

Jade Biosciences (JBIO) financials: revenue, profit and margins

Jade Biosciences (JBIO) generated about n/a in revenue and -$153 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Jade Biosciences profitable?+

Jade Biosciences reported about -$153 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on JBIO: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with JBIO

CompareIntrinsic value

NTHINeonC Technologies Holdings

$3.17+3.26%10

SLNSilence Therapeutics plc

$19.80+0.10%10

SEPNSepterna, Inc.

$47.88+9.57%46

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

NKTXNkarta Inc.

$1.73+13.07%10

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

SCYXScynexis, Inc.

$3.84-2.54%40

HROWHarrow Inc.

$28.75+0.74%46

Held by ETFs

JBIO is in 16 US ETFs. The largest of them, with JBIO's weight in each:

Spot a number that looks wrong? Check it in JBIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JBIO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.